November 18, 2026
Health news, explained with evidence
LIVE

Head-to-Head Trial Compares Interleukin Inhibitors for Psoriatic Arthritis

❤️ Conditions & Care 2 min read 👁 11

A clinical trial presented at the American College of Rheumatology conference showed that bimekizumab achieved higher rates of joint symptom improvement in psoriatic arthritis patients than risankizumab over six months.

Head-to-Head Trial Compares Interleukin Inhibitors for Psoriatic Arthritis❤️Conditions & Care

Photo: Medical Xpress

Key points

  • Bimekizumab led to a 50 percent symptom improvement in 55 percent of patients at six months compared to 44 percent for risankizumab.
  • The clinical trial involved 553 adults with active psoriatic arthritis and evaluated both drugs head-to-head over a six-month period.
  • Candida fungal infections occurred slightly more often with bimekizumab, while overall serious adverse event rates remained low for both therapies.

A head-to-head clinical trial presented at the American College of Rheumatology conference in Orlando, Florida, suggests that the dual interleukin inhibitor bimekizumab may provide greater joint symptom relief for adults with active psoriatic arthritis than risankizumab.

The trial evaluated 553 adult participants with active psoriatic arthritis who were randomly assigned to receive regular injections of either bimekizumab or risankizumab. Researchers measured success using the ACR50 standard, which represents at least a 50 percent improvement in disease activity. At four months, 50 percent of participants receiving bimekizumab reached this benchmark compared to 38 percent of those taking risankizumab. By six months, response rates rose to 55 percent for bimekizumab and 44 percent for risankizumab.

Both biologic medications work by blocking interleukins, which are chemical messengers that drive systemic inflammation. However, bimekizumab, approved by the U.S. Food and Drug Administration in 2023, targets two interleukins, whereas risankizumab, approved in 2019, targets one. Serious side effects were documented in under 2 percent of participants taking bimekizumab and approximately 3 percent of those taking risankizumab. Candida fungal infections occurred in 3 percent of the bimekizumab group compared to 1 percent in the risankizumab group due to the drugs' immune-dampening mechanisms.

What to know: While comparative clinical trials offer helpful data on drug performance, treatment efficacy and side effect profiles differ among individuals. Patients living with psoriatic arthritis should consult their doctor or specialist before making any changes to their treatment plan.

Source Medical Xpress — medicalxpress.com/news/2026-11-trial-reveals-immune-dampening-drug.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.